Story perspectives

Houston RX Recalls 64 Tirzepatide Niacinamide Vials for Sterility Issues

By Drooid · Oct 20, 2026, 2:19 AM UTC · How we work

Summary

Story summary

Houston RX LLC recalled 64 vials of tirzepatide-niacinamide after FDA inspection found sterility issues.
The FDA classified the recall as Class II, indicating temporary or reversible health risks.
Inspectors documented 14 violations, such as exposed skin, reversed cleanroom pressure, and microbial growth in ISO 5 hood.
Certificates were marked for research use only while niacinamide met dietary-supplement standards.
Patients should keep the vials, report issues to FDA MedWatch, and consult prescribers.

1 of 1

Story summary

Houston RX LLC recalled 64 vials of tirzepatide-niacinamide after FDA inspection found sterility issues.
The FDA classified the recall as Class II, indicating temporary or reversible health risks.
Inspectors documented 14 violations, such as exposed skin, reversed cleanroom pressure, and microbial growth in ISO 5 hood.
Certificates were marked for research use only while niacinamide met dietary-supplement standards.
Patients should keep the vials, report issues to FDA MedWatch, and consult prescribers.